NanOlogy
  • Home
  • About
  • Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
    • Partnering Opportunities
  • News & Publications
    • Recent News Highlights
    • Press Release Archives
    • NanOlogy In the News
    • Presentations & Publications Archive
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
February 19, 2019 in Home Page, Presentations

ASCO-GU19 Poster: Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts

NanOlogy 1 Like Post Comments Off on ASCO-GU19 Poster: Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts

ASCO-GU19 Poster: Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts

Read More
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal